gpt-dict.com

錳 Manganese × 骨質疏鬆症

結論：證據支持

錳對骨質疏鬆的臨床證據極度薄弱：唯一正向 RCT（Strause/Saltman 1994, n=59，2 年）為鈣+銅+鋅+錳之 2x2 factorial 組合試驗，每組僅約 15 人且以 BMD 為終點，數學上根本無法分離錳的獨立貢獻；Harvard 明確表示『沒有任何以錳補充劑研究骨健康的臨床試驗』，BHOF、Endocrine Society、ACOG 三大學會骨鬆指引完全未提錳，Mayo / Cleveland Clinic 的骨健康清單也將錳排除。

C 🟠 C 薄弱證據 已發布 ✨ low — community discussion mostly non-commercial
⚠️ 標記 🇹🇼 台灣在地警示 💊 檢驗 / 藥物交互作用

錳對骨質疏鬆的臨床證據極度薄弱：唯一正向 RCT（Strause/Saltman 1994, n=59，2 年）為鈣+銅+鋅+錳之 2x2 factorial 組合試驗，每組僅約 15 人且以 BMD 為終點，數學上根本無法分離錳的獨立貢獻；Harvard 明確表示『沒有任何以錳補充劑研究骨健康的臨床試驗』，BHOF、Endocrine Society、ACOG 三大學會骨鬆指引完全未提錳，Mayo / Cleveland Clinic 的骨健康清單也將錳排除。

機轉合理（蛋白多醣合成輔因子、MnSOD），但人體臨床終點證據近乎空白，符合 C 級（薄弱證據／機轉合理 + 少量人體研究 + 學會 insufficient evidence），未到 U 級僅因有 1994 組合 RCT 與機轉支撐。

⚖️

評分透明度

所有分數由 7 層證據引擎計算，過程公開可查
原始分數 0.48
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 已發布
信心度
81%
證據方向一致性高
證據層級
E7
單篇小型隨機對照試驗

各層「支持此療效」的程度

分數越低＝該層越不支持
L2 PubMed原始文獻
0.40
L1 Examine國際基準
0.50
L3 機轉生理合理性
0.50
L11 AI 複核獨立判讀
0.50
L5 臨床機構權威立場
0.55
不支持 中性 / 混合 支持
▸查看完整決策路徑（audit trail）
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.482
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals
PMID: 8027856 1994 隨機對照試驗 n = 59
結論：Spinal BMD declined significantly in the placebo group. The combined calcium + trace minerals (Cu/Zn/Mn) arm was the only group in which bone loss was halted (no significant decline from baseline). Calcium alone or trace minerals alone produced intermediate, non-significant trends. The trial CANNOT isolate a manganese-specific effect — manganese was always co-administered with copper and zinc, and the only positive arm also contained calcium. Small sample per arm (~15) and surrogate endpoint (BMD, not fracture).
🟠 品質有限 ⚠️ 廠商資助 效應量：Spinal BMD change over 2y: placebo −3.5%, Ca-only −1.9% (NS), trace-mineral-only −1.6% (NS), Ca + trace minerals +1.3% (significant vs placebo). Manganese contribution not separable.
前往 PubMed
Lower serum manganese concentrations in patients with osteoporosis
PMID: 2407097 1990 Other n = 39
結論：Osteoporotic women had serum manganese roughly 25% of age-matched controls and showed a 4-fold greater rise in plasma manganese after an oral manganese challenge, suggesting lower manganese status. This is a small case-control association — it does NOT demonstrate that manganese supplementation prevents or treats osteoporosis, only that low manganese status may correlate with the disease.
🟠 品質有限 學術資助 效應量：Mean serum Mn substantially lower in osteoporotic group; no clinical endpoint
前往 PubMed
Trace Elements in Human Nutrition (II) - An Update
PMID: 32042399 2020 Other
結論：Reviews mechanistic role of manganese as a cofactor for glycosyltransferases involved in proteoglycan synthesis in cartilage and bone matrix, and cites the Strause/Saltman 1994 trial as the principal human bone-supplementation evidence. Concludes that isolated manganese RCTs in osteoporosis are absent and that any bone benefit cannot be separated from co-administered minerals. Mechanistic narrative; no quantitative pooling, no GRADE.
🟠 品質有限 學術資助 效應量：Not a quantitative review
前往 PubMed
Manganese in health and disease
PMID: 24470093 2013 Other
結論：Notes that overt manganese deficiency in humans is exceedingly rare and that bone-related evidence for supplementation rests largely on a single small combination trial (Strause 1994) plus animal data on cartilage proteoglycan synthesis. Authors emphasize that the narrow window between adequacy (~1.8-2.3 mg/day AI) and neurotoxic exposure cautions against routine supplementation. No supportive evidence for isolated manganese as an osteoporosis intervention.
學術資助 效應量：Qualitative; cautionary on supplementation
前往 PubMed
Relationship between blood manganese and bone mineral density and bone mineral content in adults: A population-based cross-sectional study
PMID: 36269752 2022 Other n = 14,180
結論：Reported a non-linear association: higher dietary manganese intake was associated with higher BMD at the femoral neck and lower odds of osteoporosis in certain subgroups (notably postmenopausal women), with a possible inverted-U pattern. Cross-sectional design CANNOT establish causality; dietary manganese co-varies with overall diet quality, fruit/vegetable/whole-grain intake, and other minerals. No supplementation intervention.
🟠 品質有限 學術資助 效應量：Adjusted odds ratios in subgroups; not from an interventional trial
前往 PubMed

L4a US FDA
支持
NUTRIENT SUPPLEMENT 來源↗
L4b EU EFSA
支持
contributes to normal energy-yielding metabolism; contributes to the maintenance of normal bones; contributes to the normal formation of connective tissue; contributes to the protection of cells from oxidative stress 來源↗
L4c UK NHS
謹慎
You should be able to get all the manganese you need from your daily diet. Taking high doses of manganese for long periods of time might cause muscle pain, nerve damage and other symptoms, such as fatigue and depression. For most people, taking 4mg or less of manganese supplements a day is unlikely to cause any harm. For older people, who may be more sensitive to manganese, taking 0.5mg or less… 來源↗
L4d TW TFDA / 衛福部
支持
形態屬膠囊狀、錠狀且標示有每日食用限量之食品，在每日食用量中，其錳之總含量不得高於11 mg。限於補充食品中不足之營養素時使用。 來源↗
L4e WHO
謹慎
A provisional guideline value of 0.08 mg/L for manganese in drinking-water is established based on neurological effects in rats; emerging evidence supports the oral route as a potentially important route of exposure for manganese toxicity. 來源↗

L5a NIH Office of Dietary Supplements
謹慎
Manganese is an essential trace element that is naturally present in many foods and available as a dietary supplement. Manganese is a cofactor for many enzymes, including manganese superoxide dismutase, arginase, and pyruvate carboxylase. Through the action of these enzymes, manganese is involved in amino acid, cholesterol, glucose, and carbohydrate metabolism; reactive oxygen species scavengin… 來源↗
L5b Mayo Clinic
中性
L5c Cleveland Clinic
中性
L5d Harvard Health
中性
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
中性
— 本適應症無對應資料

PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 低度
低中高
📍立場總覽

台灣社群（PTT/Dcard/Mobile01）幾乎沒有「錳用於骨質疏鬆」的獨立討論。錳被視為微量礦物質，極少作為單方保健品被鄉民實測；即使在 MuscleBeach、Mancare 等版討論鈣鎂鋅、ZMA 等與骨骼相關的補充品時，也完全沒人提到錳對骨鬆的效果。少數提及「錳防骨鬆」的內容皆出自商業健康媒體（TVBS、營養新知、大紀元）而非社群真實經驗，屬 L10d 業配媒體範疇，不計入本層。屬冷門題，無在地社群討論。

💬社群實感

無共識（台灣社群無錳針對骨質疏鬆的實測討論）

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

挺立鈣強力錠 60+28錠 NT$729

代表來源 ↗
L10b · TFDA 法定身份 官方認定

不得標示或廣告涉及醫療效能

來源 ↗

  • 雙磷酸鹽類藥物（如 alendronate、zoledronic acid）
  • 負重與肌力運動
  • 飲食中攝取足量鈣與維生素 D
✓ PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 5 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v9 engine_version: v1.0 claim_id: CLM-COND-osteoporosis-INT-manganese-001
查看 ClaimReview 結構化資料 (JSON-LD) 
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-osteoporosis-INT-manganese-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "錳能改善骨質疏鬆症",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}